Details of the Drug Combination

General Information of Drug Combination (ID: DCL6IQR)

Drug Combination Name
JZL195 Trioxsalen
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs JZL195   DMEOCKZ Trioxsalen   DM53BDW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 3.06
Bliss Independence Score: 3.06
Loewe Additivity Score: 16.76
LHighest Single Agent (HSA) Score: 16.76

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of JZL195
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
JZL195 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Acyloxyacyl hydrolase (neutrophil) TT2EJXQ AOAH_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of Trioxsalen
Disease Entry ICD 11 Status REF
Skin sensitivity to sun N.A. Approved [3]
Vitiligo ED63.0 Approved [4]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63.
3 Trioxsalen FDA Label
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015